<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753012</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000121</org_study_id>
    <nct_id>NCT00753012</nct_id>
  </id_info>
  <brief_title>Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults</brief_title>
  <official_title>An In Depth Cardiovascular Study of Lisdexamfetamine (LDX; Vyvanse) in Healthy and Treated Hypertensive Adults With Attention Deficit Hyperactivity Disorder (ADHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about the effects of a medication called
      Vyvanse on the heart (cardiovascular system). The U.S. Food and Drug Administration (FDA) has
      approved Vyvanse for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). People
      who have ADHD have trouble paying attention, organizing, and planning; these symptoms can
      cause problems at work, socially and at home.

      Vyvanse (also known as Lisdexamfetamine) is a stimulant class medication. There have been
      reports of serious cardiovascular effects in children and adults treated with stimulants.
      While there is no definite evidence that these events were related to the use of stimulants,
      the deaths have raised questions about the cardiovascular safety of stimulants.

      The study will involve in-depth cardiovascular tests, namely echocardiograph (ultrasound of
      the heart) and cardiopulmonary exercise test (also called stress test; subjects exercise on a
      bicycle while measuring their heart activity and breathing is monitored by cardiologists).

      The investigators predict to see changes in blood pressure and heart rate as shown in
      previous clinical studies, and that the in-depth cardiovascular tests will provide new
      insights into the cardiovascular impact of stimulants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricle Size</measure>
    <time_frame>3-6 months</time_frame>
    <description>Size of the heart's left ventricle chamber (Left Ventricular End Diastolic Dimension; LVEDD) following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac Function Index (E/A Ratio)</measure>
    <time_frame>3-6 months</time_frame>
    <description>Left ventricle diastolic function index, following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure at Maximum Exertion</measure>
    <time_frame>3-6 months</time_frame>
    <description>Diastolic blood pressure (DBP) at maximum exertion following 3-6 months of stimulant medication, according to cardiopulmonary exercise testing (CPET)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder (ADHD)</condition>
  <arm_group>
    <arm_group_label>Lisdexamfetamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults who meet DSM-IV-TR criteria for ADHD.
Group 1 is normotensive adults; Group 1 does not have high blood pressure. Group 2 is primary hypertensive adults; Group 2 does have high blood pressure and is being treated with stable doses of hypertensive medications achieving a blood pressure of &lt;135/85.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisdexamfetamine</intervention_name>
    <description>Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.</description>
    <arm_group_label>Lisdexamfetamine</arm_group_label>
    <other_name>Vyvanse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female outpatients 18-60 years of age.

          2. A current DSM-IV-TR diagnosis of ADHD, confirmed by the Adult ADHD Clinical Diagnostic
             Scale (ACDS) at Screening.

          3. In phase two only; Stage I primary hypertension (SBP 140-159 mm Hg/DBP 90-99 mm Hg) as
             defined by Joint National Committee on Prevention, Detection, Evaluation, and
             Treatment of High Blood Pressure (Chobanian et al, 2003).

          4. In phase two only; Treatment with stable doses of up to two FDA approved
             antihypertensive medications achieving a stable blood pressure of &lt;135/85. Acceptable
             classes of medications include diuretics, beta-blockers, angiotensin-converting-enzyme
             (ACE) inhibitors or receptor blockers, aldosterone antagonists, calcium-channel
             blockers (Rosendorff et al, 2007).

        Exclusion Criteria:

          1. Pregnant or nursing females.

          2. Clinically significant cardiovascular history, including angina, syncope, thrombosis,
             aneurysm, myocardial infarction, myocarditis, valvular disease, heart failure, or
             arrhythmia. Hypertension is exclusionary in phase one subjects.

          3. In phase two; hypertension is not exclusionary, however blood pressure with
             antihypertensive treatment of â‰¥135/85 at baseline is exclusionary.

          4. Clinically significant or unstable medical condition including pulmonary (asthma,
             edema, thrombosis), renal, hepatic, metabolic (thyroid) or neurological disorder,
             based upon a medical history.

          5. Orthopedic impairment or BMI that significantly impacts or restricts exercise
             performance testing, per clinician judgment.

          6. Any clinically unstable psychiatric conditions including suicidality, homicidality,
             bipolar disorder, psychosis.

          7. Current (within 3 months) DSM-IV-TR criteria for current abuse or dependence with any
             psychoactive substance other than nicotine, including alcohol, prescription medicines
             and/or street drugs. In addition, subjects with clinically significant histories of
             dependence on alcohol, prescription medications or &quot;street drugs&quot; will be excluded, if
             such history places subjects at heightened risk, and/or may be associated with
             cardiovascular sequelae, based on clinician judgment.

          8. Ongoing treatment with any psychotropic medication, including anxiolytics,
             antidepressants, mood stabilizers.

          9. Use of Monoamine Oxidase Inhibitors (MAOIs) including linezolid within two weeks prior
             to starting study medication.

         10. Mental retardation (IQ &lt; 75).

         11. History of intolerance or allergy to LDX.

         12. Diagnosis of glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hammerness, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <results_first_submitted>May 2, 2012</results_first_submitted>
  <results_first_submitted_qc>August 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 24, 2012</results_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Paul Hammerness, MD</investigator_full_name>
    <investigator_title>Assistant Professor Psychiatry</investigator_title>
  </responsible_party>
  <keyword>cardiovascular testing</keyword>
  <keyword>home blood pressure monitoring</keyword>
  <keyword>office home blood pressure monitoring</keyword>
  <keyword>cardiopulmonary exercise testing</keyword>
  <keyword>transthoracic echocardiography</keyword>
  <keyword>Lisdexamfetamine</keyword>
  <keyword>Vyvanse</keyword>
  <keyword>normotensive and hypertensive adults with ADHD</keyword>
  <keyword>ADHD medication.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normotensive Adults With ADHD</title>
          <description>Group 1 is comprised of adults who meet DSM-IV-TR criteria for ADHD and do not have high blood pressure.</description>
        </group>
        <group group_id="P2">
          <title>Primary Hypertensive Adults With ADHD</title>
          <description>Group 2 is comprised of adults who meet the full DSM-IV criteria for ADHD, and who also high blood pressure being treated with stable doses of up to two FDA approved hypertensive medications to achieve a stable blood pressure of &lt;135/85. High blood pressure is defined as 140-159mmHg/90-99 mmHg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible, abnormal cardiac histo</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Confounded endpoint data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normotensive Adults With ADHD</title>
          <description>Group 1 is comprised of adults who meet DSM-IV-TR criteria for ADHD and do not have high blood pressure.</description>
        </group>
        <group group_id="B2">
          <title>Primary Hypertensive Adults With ADHD</title>
          <description>Group 2 is comprised of adults who meet the full DSM-IV criteria for ADHD, and who also high blood pressure being treated with stable doses of up to two FDA approved hypertensive medications to achieve a stable blood pressure of &lt;135/85. High blood pressure is defined as 140-159mmHg/90-99 mmHg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.80" spread="11.59"/>
                    <measurement group_id="B2" value="51.33" spread="7.87"/>
                    <measurement group_id="B3" value="41.00" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricle Size</title>
        <description>Size of the heart's left ventricle chamber (Left Ventricular End Diastolic Dimension; LVEDD) following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
        <time_frame>3-6 months</time_frame>
        <population>14 subjects completed endpoint TTE; one HTN subject missed the scheduled endpoint TTE appointment.</population>
        <group_list>
          <group group_id="O1">
            <title>Normotensive Adults With ADHD</title>
          </group>
          <group group_id="O2">
            <title>Primary Hypertensive Adults With ADHD</title>
            <description>Group 2 is comprised of adults who meet the full DSM-IV criteria for ADHD, and who also high blood pressure being treated with stable doses of up to two FDA approved hypertensive medications to achieve a stable blood pressure of &lt;135/85. High blood pressure is defined as 140-159mmHg/90-99 mmHg.</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricle Size</title>
          <description>Size of the heart's left ventricle chamber (Left Ventricular End Diastolic Dimension; LVEDD) following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
          <population>14 subjects completed endpoint TTE; one HTN subject missed the scheduled endpoint TTE appointment.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.42" spread="7.07"/>
                    <measurement group_id="O2" value="43.57" spread="6.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Function Index (E/A Ratio)</title>
        <description>Left ventricle diastolic function index, following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
        <time_frame>3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normotensive Adults With ADHD</title>
          </group>
          <group group_id="O2">
            <title>Primary Hypertensive Adults With ADHD</title>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Function Index (E/A Ratio)</title>
          <description>Left ventricle diastolic function index, following 3-6 months of stimulant medication, according to cardiac ultrasound (transthoracic echocardiogram; TTE)</description>
          <units>cm/sec/cm/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="0.48"/>
                    <measurement group_id="O2" value="1.36" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure at Maximum Exertion</title>
        <description>Diastolic blood pressure (DBP) at maximum exertion following 3-6 months of stimulant medication, according to cardiopulmonary exercise testing (CPET)</description>
        <time_frame>3-6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normotensive Adults With ADHD</title>
          </group>
          <group group_id="O2">
            <title>Primary Hypertensive Adults With ADHD</title>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure at Maximum Exertion</title>
          <description>Diastolic blood pressure (DBP) at maximum exertion following 3-6 months of stimulant medication, according to cardiopulmonary exercise testing (CPET)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.43" spread="11.97"/>
                    <measurement group_id="O2" value="85.00" spread="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Normotensive Adults With ADHD</title>
          <description>Group 1 is comprised of adults who meet DSM-IV-TR criteria for ADHD and do not have high blood pressure.</description>
        </group>
        <group group_id="E2">
          <title>Primary Hypertensive Adults With ADHD</title>
          <description>Group 2 is comprised of adults who meet the full DSM-IV criteria for ADHD, and who also high blood pressure being treated with stable doses of up to two FDA approved hypertensive medications to achieve a stable blood pressure of &lt;135/85. High blood pressure is defined as 140-159mmHg/90-99 mmHg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>blind spot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>blurred vision</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="23" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>GI upset</sub_title>
                <description>Gastrointestinal upset</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>cold symptoms</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="78" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" events="164" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="12" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>foot pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>hand tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="22" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>heartburn</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>increased energy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="60" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="19" subjects_affected="6" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>jaw tension</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="132" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>jittery</sub_title>
                <counts group_id="E1" events="27" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="14" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>lip swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>low energy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="11" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>racing</sub_title>
                <description>Feeling 'on the go' or 'driven by a motor'</description>
                <counts group_id="E1" events="14" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>tension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>tightness in the hand</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>viral illness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>low appetite</sub_title>
                <counts group_id="E1" events="111" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle aches</sub_title>
                <counts group_id="E1" events="70" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>muscle tension</sub_title>
                <counts group_id="E1" events="21" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>muscle twitch</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="23" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="39" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="30" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>feelings of self-consciousness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>feeling flustered</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>difficulty achieving erection</sub_title>
                <counts group_id="E1" events="43" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>congestion</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="16" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paul Hammerness</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>(503)617-1040</phone>
      <email>phammerness@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

